If we do a little calculation based on the initial receipt from Lloyds pharma of $1,200,000 for the first order of viraleze and base that number on the population in UK, we can then compare the potential of the stock/sales required in India................... The mind boggles with the opportunity we are currently sitting on here!
We just need SPL to do some deals!
Email to SPL investor relations, page-24
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
